netFormulary NHS
Milton Keynes Formulary
Milton Keynes University Hospital NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes Clinical Commissioning Group
Milton Keynes Community Health Services
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

 

NHS Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation B04/P/a

Contacting Milton Keynes Hospital

      
For Haematology and Oncology:

  • During hours: Macmillan Unit on 01908 243671; Internal Ext 5111 or 5112
  • Out of hours: Advanced Nurse Practitioner on bleep 1090    

Paediatric patients:

  • During hours: Paediatric Day Community Unit on 01908 242703; Internal Ext 2703      

Pharmacy:

  • Cancer and Aseptic Services Manager on bleep 1721
  • Aseptic Unit 01908 243952
  • On-call pharmacist via switchboard 01908 660033
Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Brentuximab vedotin
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
08.01.05  Expand sub section  Protein kinase inhibitors
Abemaciclib (Verzenios®)
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Tablet 150mg

 

 
Link  NICE TA563:Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
   
AcalabrutinibBlack Triangle (Calquence®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Capsules 100mg

For use in accordance with the NICE TA (see link below).

 
Link  NICE TA689: Acalabrutinib for treating chronic lymphocytic leukaemia
   
Afatinib (Giotrif®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 20mg, 30mg, 40mg, 50mg

 

 
Link  NICE TA310: Afatinib for non-small-cell lung cancer
   
BrigatinibBlack Triangle (Alunbrig®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablets, 30mg, 90mg, 180mg

 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Link  NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
   
Cabozantinib (Cometriq®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Cometriq® Capsules 20mg, 80mg
Cabometyx® 20mg, 40mg, 60mg tablets

Notes:

NHSE Position Statement.

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Crizotinib (Xalkori®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Xalkori® Capsules 200mg, 250mg

 

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  MHRA: risk of cardiac failure with crizotinib
   
Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Sprycel® Tablets film-coated 20mg, 50mg, 80mg, 100mg, 140mg

 

 
Link  MHRA/CHM advice (May 2016): Risk of hepatitis B virus reactivation with BCR-ABL tyrosine kinase inhibitors
Link  NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Everolimus (Afinitor®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Afinitor® Tablets 2.5mg, 5mg, 10mg
Certican® Tablets 250 microgram, 750 microgram

 

 
Link  NICE TA348: Preventing Rejection in Liver Transplant
Link  NICE TA421:Everolimus with exemestane in advanced breast cancer after endocrine therapy
Link  NICE TA432:Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
   
Gefitinib (Iressa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablets 250mg

 

 
Link  Drug Safety Update: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer
   
GilteritinibBlack Triangle (Xospata®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

40mg tablets

 
Link  NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
   
Imatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Glivec® Tablets film-coated 100mg, 400mg

 

 
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
   
Lapatinib (Tyverb®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 250mg

 

 
Link  NICE TA257 Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER
   
Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Capsules 150mg, 200mg

 

 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Link  NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
OsimertinibBlack Triangle (Tagrisso®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 40mg, 80mg 

 
Link  NICE TA416: Osimertinib in non-small-cell lung cancer
Link  NICE TA621: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
Link  NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
Link  NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
   
Pazopanib (Votrient®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 200mg,400mg

 

 
Link  NICE TA 215: Pazopanib in renal cell cancer
   
Regorafenib (Stivarga® )
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablets 40mg

 

 
Link  NICE TA488:Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
   
Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 200mg

 

 
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Sorafenib for treating differentiated thyroid cancer after radioactive iodine.
   
Sunitinib (Sutent®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Capsules 12.5mg,25mg,50mg

 
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Cytotoxic Drug Temsirolimus (Torisel®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Solution for infusion 25mgper 1ml

 

 
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
   
Vemurafenib (Zelboraf®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 240mg

 

 
Link  MHRA: Risk of potentiation of radiation toxicity with vemurafenib
Link  NICE TA269: Vemurafenib for treating malignant melanoma
   
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab to top
08.01.05  Expand sub section  Tretinoin
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Cytotoxic Drug  Vandetanib  (Caprelsa®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Routine prescribing within licensed indication  

Amber 1

Specialist recommendation followed by GP initiation and continuation  

Amber 2

Specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation   

Amber 3

Specialist initiation and stabilisation followed by GP continuation  

Amber SCG

Specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline  

Red

Hospital or specialist prescribing only  

Red Red

These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.  

netFormulary